Rush Fracture Liaison Service for capturing “missed opportunities” to treat osteoporosis in patients with fragility fractures

[1] Strom O(2011)Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos 6 59-155

[2] Borgstrom F(2007)Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 465-475

[3] Kanis JA(2006)An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 7 1726-413

[4] Compston J(1997)World-wide projections for hip fracture Osteoporos Int 7 407-S112

[5] Cooper C(2010)Osteoporosis and mortality Joint Bone Spine 77 S107-382

[6] McCloskey EV(2004)A meta-analysis of previous fracture and subsequent fracture risk Bone 35 375-171

[7] Jönsson B(1980)Epidemiology of fractures of the proximal femur in Rochester, Minnesota Clin Orthop Relat Res 150 163-32

[8] Burge R(2005)Intervention thresholds for osteoporosis in the UK Bone 36 22-676

[9] Dawson-Hughes B(1997)Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older N Engl J Med 337 670-645

[10] Solomon DH(1999)Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 637-1822

[1] Strom O(2011)Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos 6 59-155

[2] Borgstrom F(2007)Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 465-475

[3] Kanis JA(2006)An estimate of the worldwide prevalence and disability associated with osteoporotic fractures Osteoporos Int 7 1726-413

[4] Compston J(1997)World-wide projections for hip fracture Osteoporos Int 7 407-S112

[5] Cooper C(2010)Osteoporosis and mortality Joint Bone Spine 77 S107-382

[6] McCloskey EV(2004)A meta-analysis of previous fracture and subsequent fracture risk Bone 35 375-171

[7] Jönsson B(1980)Epidemiology of fractures of the proximal femur in Rochester, Minnesota Clin Orthop Relat Res 150 163-32

[8] Burge R(2005)Intervention thresholds for osteoporosis in the UK Bone 36 22-676

[9] Dawson-Hughes B(1997)Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older N Engl J Med 337 670-645

[10] Solomon DH(1999)Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators JAMA 282 637-1822